# AstraZeneca PLC Appoint world-renowned expert in precision medicine as Non-Executive Director

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-appoint-world-renowned-expert-in-precision-medicine-as-non-executive-director/412763024
- Published: 2018-12-14T07:21:50+00:00
- Author: Charlotte Edwards

**[AstraZeneca PLC](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
today announced the following changes in respect of Non-Executive Directors.

**New Non-Executive Director**

With effect from 1 January 2019, Professor Tony Mok is appointed as a Non-Executive
Director and a member of the Science Committee. Biographical details for Professor
Mok are provided below.

**Retirement of Non-Executive Director**

The Company previously announced that Shriti Vadera will retire as a Director by
31 December 2018, by when she will have served as a Board member for eight years.
The Company now confirms she will leave the Board on 31 December 2018.

> **Leif Johansson, Chairman of AstraZeneca, said:** “We are very pleased to welcome
> Tony Mok to our Board and Science Committee as a leading clinical oncologist and
> world-renowned expert in precision medicine for lung cancer. He will make a significant
> contribution to AstraZeneca’s science-led transformation as we bring our science
> to more patients around the world.
> “Shriti Vadera’s eight years with the Company has included service as a member
> of both the Audit Committee and the Remuneration Committee. She has been an exceptional
> colleague during a period of pipeline renewal, as AstraZeneca returned to growth.
> Her diligence, focus and constant commitment to the Company’s success will be 
> missed. On behalf of all her Board colleagues, we thank her for her service and
> wish her every success in the future.”

**Biographical details – Professor Tony Mok BMSc, MD, FRCP(C), FRCP(Edin), FHKCP,
FHKAM(Medicine), FASCO**

Professor Tony S K Mok was trained at the University of Alberta, Canada and subsequently
completed a fellowship in medical oncology at the Princess Margaret Hospital in 
Toronto. After working as a community oncologist in Toronto, Canada for seven years,
he returned to Hong Kong in 1996 to pursue an academic career.

Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman
of the Department of Clinical Oncology at the Chinese University of Hong Kong. His
main research interest focuses on biomarker and molecular targeted therapy in lung
cancer. He was the principal investigator and first author on the landmark Iressa
Pan-Asia Study (IPASS), which was the first trial that confirmed the application
of precision medicine for advanced lung cancer. He has led and co-led multiple other
international Phase III trials, addressing various aspects of the management of 
advanced lung cancer. His work also includes clinical research on oncogene driven
lung cancer and immunotherapy and he contributes to the development of clinical 
research infrastructure in China and Asia. He co-founded the Lung Cancer Research
Group, the Chinese Thoracic Oncology Research Group and the Asia Thoracic Oncology
Research Group.

Professor Mok has contributed to over 250 articles in international peer-reviewed
journals, including the New England Journal of Medicine, Science, Lancet, Nature
Medicine and Journal of Clinical Oncology, and published multiple editorials and
textbooks. He is the past-President and current Treasurer of the International Association
for the Study of Lung Cancer (IASLC) and serves on the Board of Directors of the
American Society of Clinical Oncology (ASCO).

His work has been recognised by numerous awards including the Bonnie Addario Award
in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017,
the Paul Bunn Jr Scientific Award in 2017, the National Science and Technology Progress
Award in 2017 and the ESMO Lifetime Achievement Award in 2018.

Professor Mok is a Non-Executive Director of Hutchison China MediTech Limited and
a co-founder and the Chairman of Sanomics Limited.

In relation to Professor Mok’s appointment, except as set out above, no disclosure
obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority’s
Listing Rules.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on: